Physician profile
Sajjad Mohammad
NPI 1033290242
$16,155.90
in general payments reported to CMS, 2019-2025
20 companies · $3,437 in 2025
The $3,437 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,010 · 2020: $531 · 2021: $1,933 · 2022: $1,870 · 2023: $2,294 · 2024: $3,080 · 2025: $3,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,776 · Travel and Lodging: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,775.93 |
| Travel and Lodging | $1,035.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $9,384.95 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,276.99 | 2019-2025 | Biktarvy |
| Janssen Products, LP | $2,224.09 | 2019-2021 | |
| Janssen Biotech, INC. | $823.67 | 2019-2023 | Symtuza |
| Lilly USA, LLC | $267.75 | 2019-2024 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $208.69 | 2023 | Austedo Xr, Austedo |
| Abbvie INC. | $176.25 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $138.27 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $122.43 | 2024 | Airsupra |
| Novo Nordisk INC | $117.50 | 2019-2025 | Ozempic |
| Neurocrine Biosciences, INC. | $78.63 | 2024 | Ingrezza |
| Paratek Pharmaceuticals, INC. | $77.49 | 2025 | Nuzyra |
| Theratechnologies INC. | $46.64 | 2022 | |
| Amgen INC. | $43.01 | 2019-2024 | Uplizna |
| Horizon Therapeutics Plc | $42.69 | 2023 | Uplizna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.06 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Glaxosmithkline, LLC. | $23.32 | 2023 | Trelegy Ellipta |
| Indivior INC. | $21.78 | 2025 | Sublocade |
| Exact Sciences Corporation | $18.21 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.